Table 4 Significantly AD-associated pathways from pathway-based analyses
From: Genome-wide analysis of genetic predisposition to Alzheimer’s disease and related sex disparities
Pathway | Pathway GSEA ID | Number of genes | Plan 1 (males and females) | Plan 2 (only males) | Plan 3 (only females) | |||
|---|---|---|---|---|---|---|---|---|
χ 2 | p value | χ 2 | p value | χ 2 | p value | |||
Mitochondrial protein import | M590 | 58 | 4939.52 | 3.83E–44 | 2741.07 | 4.65E–12 | 3622.61 | 7.07E–25 |
Chylomicron-mediated lipid transport | M14162 | 16 | 4180.44 | 1.11E–41 | 1968.73 | 7.13E–14 | 2854.57 | 4.86E–25 |
Nectin adhesion pathwaya | M72 | 30 | 5872.18 | 6.52E–39 | 3393.55 | 6.09E–09 | 4310.19 | 1.39E–19 |
HDL-mediated lipid transport | M5056 | 15 | 4184.21 | 5.08E–38 | 2195.67 | 1.98E–12 | 2779.67 | 6.00E–20 |
Lipoprotein metabolism | M3462 | 28 | 5221.10 | 2.11E–37 | 3011.78 | 1.86E–10 | 3825.74 | 3.47E–20 |
Lipid digestion, mobilization and transport | M1023 | 46 | 5889.33 | 5.64E–36 | 3631.17 | 4.67E–09 | 4448.01 | 2.37E–18 |
E-cadherin stabilization pathwaya | M232 | 42 | 5976.76 | 1.72E–27 | 3670.50 | 9.69E–05 | 4517.86 | 3.67E–12 |
Immunoregulatory interactions between a lymphoid and a nonlymphoid cell | M8240 | 70 | 6335.34 | 4.04E–19 | 4056.72 | 2.39E–07 | 4720.40 | 8.48E–11 |
Adherens junctions interactions | M11980 | 27 | 7432.11 | 7.54E–18 | 5204.26 | 1.54E–05 | 6110.31 | 1.67E–10 |
Cell–cell junction organization | M820 | 56 | 8940.07 | 1.34E–17 | 6464.13 | 2.61E–04 | 7758.51 | 4.48E–11 |
Cell junction organization | M19248 | 78 | 10,542.40 | 1.71E–17 | NS | NS | 9337.94 | 6.78E–11 |
NF-κB atypical pathwaya | M26 | 17 | 1630.19 | 3.26E–07 | NS | NS | NS | NS |
Platelet sensitization by LDL | M919 | 16 | 994.69 | 5.38E–04 | NS | NS | 1002.45 | 4.21E–04 |
Signaling by EGFR in cancer | M563 | 109 | 8116.41 | 6.44E–04 | NS | NS | NS | NS |
Trans-Golgi network vesicle budding | M539 | 60 | 2967.31 | 7.13E–04 | NS | NS | NS | NS |
FAS (CD95) signaling pathwaya | M94 | 38 | 2322.57 | 7.15E–04 | NS | NS | NS | NS |
Golgi-associated vesicle biogenesis | M1877 | 53 | 2758.56 | 7.26E–04 | NS | NS | NS | NS |
Signaling by PDGF | M2049 | 122 | 9443.31 | 7.57E–04 | NS | NS | NS | NS |
mRNA processing | M2531 | 161 | 6183.56 | 7.93E–04 | NS | NS | NS | NS |
Prostacyclin signaling through prostacyclin receptor | M926 | 19 | NS | NS | NS | NS | 1579.24 | 4.50E–05 |
G-protein activation | M13115 | 27 | NS | NS | NS | NS | 2138.82 | 6.18E–05 |
ADP signaling through P2Y purinoceptor 12 | M841 | 21 | NS | NS | NS | NS | 1680.25 | 1.54E–04 |
ADP signaling through P2Y purinoceptor 1 | M811 | 25 | NS | NS | NS | NS | 2101.01 | 2.71E–04 |
Glucagon-type ligand receptors | M10322 | 33 | NS | NS | NS | NS | 2483.81 | 4.51E–04 |
Signal amplification | M9379 | 31 | NS | NS | NS | NS | 2412.57 | 4.99E–04 |
Gβγ signaling through PI3Kγ | M14301 | 25 | NS | NS | NS | NS | 1808.24 | 5.30E–04 |